A Partial Toll-like Receptor 4 Agonist Attenuates Pain While Maintaining Immunosufficiency

Activation of Toll-like Receptor 4 (TLR4) from infection or tissue damage/stress is a contributing factor to many diseases including chronic pain. Many of these pain conditions are associated with chronically elevated inflammatory cytokine expression or autoimmune dysregulation (e.g., rheumatoid arthritis, Crohn ’s disease). Current treatment includes biologics that target signaling pathways downstream of TLR4. These drugs reduce pain by reducing cytokine detection and function; many target TNF-alpha.
Source: The Journal of Pain - Category: Materials Science Authors: Source Type: research